Dexlansoprazole is a second-generation proton pump inhibitor,
which
is used to treat gastroesophageal reflux disease and erosive esophagitis.
It is usually synthesized by asymmetric sulfur oxidation through the
Kagan reaction. However, due to the difficulty in controlling the
degree of sulfur oxidation, the impurity content changes in different
batches in the preparation process, resulting in the low quality of
obtained dexlansoprazole, which is difficult to meet the requirements
of Pharmacopeia. To control the oxidation degree of sulfur and accurately
judge the reaction end point, in situ infrared spectroscopy
was used to monitor the reaction state in the synthesis of dexlansoprazole.
This method has been successfully verified in kilogram-scale production,
showing a final product yield of 72.9–73.6% with a purity of
99.86–99.89%.